166 related articles for article (PubMed ID: 17063333)
1. [Treatment of breast cancer: from hormones to antibodies].
Eucker J; Emde A; Possinger K
Internist (Berl); 2006 Dec; 47(12):1223-4, 1226-8. PubMed ID: 17063333
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
4. Perspective of trastuzumab treatment.
Iwata H
Breast Cancer; 2007; 14(2):150-5. PubMed ID: 17485899
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic advances in breast cancer].
Pestalozzi BC
Ther Umsch; 2006 Apr; 63(4):255-61. PubMed ID: 16689456
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment of breast cancer.
Akerley WL
R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
[No Abstract] [Full Text] [Related]
7. [Sequencing of adjuvant treatment after surgery for invasive breast cancer].
Petit T; Claude L; Carrie C
Cancer Radiother; 2004 Feb; 8(1):54-8. PubMed ID: 15093202
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer: metastatic.
Johnston S; Stebbing J
Clin Evid; 2002 Jun; (7):1579-602. PubMed ID: 12230774
[No Abstract] [Full Text] [Related]
9. [New data concerning breast carcinoma. A report on the 34th Meeting of the American Society of Clinical Oncology, Los Angeles, Calif., USA, May 16-19, 1998].
Gerber B; Krause A
Gynakol Geburtshilfliche Rundsch; 1999; 39(3):136-9. PubMed ID: 10420058
[No Abstract] [Full Text] [Related]
10. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637
[TBL] [Abstract][Full Text] [Related]
11. [Management of metastatic HER2-positive breast cancer: present and future].
Guiu S; Coudert B; Favier L; Arnould L; Fumoleau P
Bull Cancer; 2010 Mar; 97(3):365-83. PubMed ID: 20176546
[TBL] [Abstract][Full Text] [Related]
12. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Smith I; Procter M; Gelber RD; Guillaume S; Feyereislova A; Dowsett M; Goldhirsch A; Untch M; Mariani G; Baselga J; Kaufmann M; Cameron D; Bell R; Bergh J; Coleman R; Wardley A; Harbeck N; Lopez RI; Mallmann P; Gelmon K; Wilcken N; Wist E; Sánchez Rovira P; Piccart-Gebhart MJ;
Lancet; 2007 Jan; 369(9555):29-36. PubMed ID: 17208639
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
14. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
Haq B; Geyer CE
Womens Health (Lond); 2009 Mar; 5(2):135-47. PubMed ID: 19245352
[TBL] [Abstract][Full Text] [Related]
15. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
[TBL] [Abstract][Full Text] [Related]
17. New drugs in breast cancer.
Iqbal S; Miller WR
Expert Opin Pharmacother; 2001 Jun; 2(6):975-85. PubMed ID: 11585013
[TBL] [Abstract][Full Text] [Related]
18. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
Palmieri C; Shah D; Krell J; Gojis O; Hogben K; Riddle P; Ahmad R; Tat T; Fox K; Porter A; Mahmoud S; Kirschke S; Shousha S; Gudi M; Coombes RC; Leonard R; Cleator S
Clin Breast Cancer; 2011 Apr; 11(2):93-102. PubMed ID: 21569995
[TBL] [Abstract][Full Text] [Related]
19. Elderly breast cancer patients: adjuvant chemotherapy and adjuvant endocrine therapy.
Biganzoli L; Aapro M
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):137-42. PubMed ID: 15990438
[TBL] [Abstract][Full Text] [Related]
20. [Targeting ErbB receptors in breast cancer].
Fumoleau P; Campone M; Coudert B; Mayer F; Favier L; Ferrant E
Bull Cancer; 2007; 94(7 Suppl):F147-70. PubMed ID: 17964992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
